Weizmann Institute physicists create a new 3D imaging technique that speeds up and simplifies the process of reconstructing 3D images. The system uses a transparent fluorescent screen to capture light particles emitted by flashes, allowing for precise distance measurements between the screen and object points.
SourceAmerican Committee for the Weizmann Institute of Science·DateAug 27, 1996
A breakthrough in basic chemistry developed by University at Buffalo scientists has the potential to expand dramatically the variety and potency of new pharmaceutical compounds. The method uses a chiral catalyst to synthesize biologically important compounds with specific chemical structures.
Researchers developed polymer-based photonic materials that can store thousands of times more data than traditional CDs. The new materials utilize two-photon absorption to enable efficient color movie storage and allow for compact data storage, making them ideal for archiving large quantities of images.
A biological 'switch' has been discovered in plants that controls their leaf movements, opening them at dawn and closing them at dusk. This discovery could lead to new applications such as preventing crop wilting during drought or altering the time of flowering.
SourceAmerican Committee for the Weizmann Institute of Science·DateAug 27, 1996
A groundbreaking study reveals that brain cells belong to multiple groups and change their affiliation according to the task, coordinating processes involved in vision, hearing, and movement control. This finding has implications for neurology and computer science.
SourceAmerican Committee for the Weizmann Institute of Science·DateAug 27, 1996
The new test developed by Prof. Roald Nezlin of the Weizmann Institute solves a problem with standard tests by measuring the quantity of DNA in harmful complexes, indicating effective treatment. This approach could also be used to measure antibody complexes involved in other autoimmune diseases.
SourceAmerican Committee for the Weizmann Institute of Science·DateAug 27, 1996
A new monoclonal antibody called ReoPro has significantly reduced life-threatening complications from angioplasty both immediately and up to three years after treatment. The study found that patients treated with ReoPro had a 59% reduction in overall death, recurrent heart attacks, and urgent repeat angioplasty or by-pass surgery.